北京白花檵木生物科技

Beijing Loropetalum Biotechnology is a Chinese biopharmaceutical company focused on the research and development of traditional Chinese medicine (TCM) and botanical drug products. The company's lead candidate is Jimu Keli (Loropetalum Granules), a botanical drug derived from Loropetalum chinense extracts. Jimu Keli has been evaluated in Phase II clinical trials in China for the treatment of digestive system disorders, specifically chronic non-atrophic gastritis with erosion and hemorrhagic gastritis. Although clinical development of Jimu Keli was voluntarily suspended, the company remains dedicated to exploring the therapeutic potential of botanical extracts.